El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

GEM14-v4.pdf (297.03 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-11-02

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/207533

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1182/blood.2022019531

Resum

From November 2014 to May 2017, 332 patients homogeneously treated with bortezomib, lenalidomide, and dexamethasone (VRD) induction, autologous stem cell transplant, and VRD consolidation were randomly assigned to receive maintenance therapy with lenalidomide and dexamethasone (RD; 161 patients) vs RD plus ixazomib (IRD; 171 patients). RD consisted of lenalidomide 15 mg/d from days 1 to 21 plus dexamethasone 20 mg/d on days 1 to 4 and 9 to 12 at 4-week intervals, whereas in the IRD arm, oral ixazomib at a dose of 4 mg on days 1, 8, and 15 was added. Therapy for patients with negative measurable residual disease (MRD) after 24 cycles was discontinued, whereas those who tested positive for MRD remained on maintenance with RD for 36 more cycles. After a median follow-up of 69 months from the initiation of maintenance, the progression-free survival (PFS) was similar in both arms, with a 6-year PFS rate of 61.3% and 55.6% for RD and IRD, respectively (hazard ratio, 1.136; 95% confidence interval, 0.809-1.603). After 2 years of maintenance, treatment was discontinued in 163 patients with negative MRD, whereas 63 patients with positive MRD continued with RD therapy. Maintenance discontinuation in patients tested negative for MRD resulted in a low progression rate (17.2% at 4 years), even in patients with high-risk features. In summary, our results show the efficacy of RD maintenance and support the safety of maintenance therapy discontinuation in patients with negative MRD at 2 years. This trial was registered at www.clinicaltrials.gov as #NCT02406144 and at EudraCT as 2014-00055410.

Matèries

Mieloma múltiple, Quimioteràpia

Matèries (anglès)

Multiple myeloma, Chemotherapy

Citació

Col·leccions

Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

ROSIÑOL DACHS, Laura, ORIOL, Albert, RIOS, Rafael, BLANCHARD, Maria jesús, JARQUE, Isidro, BARGAY, Joan, HERNÁNDEZ, Miguel teodoro, CABANAS, Valentín, CARRILLO CRUZ, Estrella, SUREDA, Anna, MARTÍNEZ LÓPEZ, Joaquín, KRSNIK, Isabel, GONZÁLEZ, María esther, CASADO, Luís felipe, MARTÍ, Josep maria, ENCINAS, Cristina, ARRIBA, Felipe de, PALOMERA, Luis, SAMPOL, Antonia, GONZALEZ MONTES, Yolanda, CABEZUDO, Elena, PAIVA, Bruno, PUIG, Noemí, CEDENA, Maria teresa, CRUZ, Javier de la, MATEOS, María victoria, SAN MIGUEL, Jesús, LAHUERTA, Juan josé, BLADÉ, J. (joan). Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma. _Blood_. 2023. Vol. 142, núm. 18, pàgs. 1518-1528. [consulta: 7 de gener de 2026]. ISSN: 1528-0020. [Disponible a: https://hdl.handle.net/2445/207533]

Exportar metadades

JSON - METS

Compartir registre